FindTrial
Sign In

The comparison of remifentanil infusion facilitated awake extubation to deep extubation with LMA exchange in patients undergoing dacrystorhinostomy surgery

The comparison of remifentanil infusion facilitated awake extubation to deep extubation with LMA exchange in patients undergoing dacrystorhinostomy surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029532
Enrollment
Unknown
Registered
2020-02-03
Start date
2018-06-04
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dacryocystitis surgery anesthesia

Interventions

R-L:Refenmitanile infusion rate 0.06ug/kg/min
R-M:Refenmitanile infusion rate 0.08ug/kg/min
R-H:Refenmitanile infusion rate 0.1ug/kg/min
D-LMA:extubation with LMA exchange at a deep anesthesia level

Sponsors

Tianjin Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) ASA I-II, adult patients with chronic dacryocystitis; (2) patients with elective surgery, have complete clinical data; (3) obtain informed consent of patients or guardians.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of upper respiratory tract infection in the past two weeks; (2) BMI=30; (3) patients airway anatomical abnormalities, bronchial asthma and other respiratory hyperresponsiveness diseases; (4) history of arrhythmia, congenital heart disease, mental disorders or other mental development disorders.

Design outcomes

Primary

MeasureTime frame
Cough;Breath holding;Laryngeal spasm;Sore throat;Hoarseness;—

Secondary

MeasureTime frame
Blood pressure;—

Countries

China

Contacts

Public ContactSun Ruiqiang

Tianjin Eye Hospital

38940444@qq.com+86 18602643440

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026